Medical Developments International Ltd. reported a 9% increase in group revenue to AUD 42.6 million for the fiscal year ended June 30, 2026, driven by growth in its pain-management portfolio. The company’s pain-management revenue rose 21% to AUD 31 million, offsetting a 15% decline in respiratory segment sales to AUD 11.6 million.
Pain-management revenue in Australia increased 16% to AUD 17.9 million, while European sales grew 12% to AUD 9 million. Revenue from other regions climbed to AUD 4.1 million, reflecting a strong expansion outside core markets. Hospital volumes for Penthrox, the company’s flagship pain-management product, reached 48,000 units in Australia, up 28% year-over-year.
Earnings before interest and tax (EBIT) for the pain-management segment surged 50% to AUD 9.4 million, supported by a AUD 1 million pricing benefit in Australia, a AUD 1.8 million increase in underlying demand, and a AUD 1.1 million gain from partner stocking changes. These gains were partially offset by a AUD 1.4 million reduction in European transfer prices following the transition to partner supply, a AUD 500,000 decline in respiratory demand, and a AUD 900,000 foreign exchange loss compared with a AUD 1.6 million gain in the prior year. A AUD 400,000 refund of U.S. tariffs provided additional support.
Free cash flow improved to AUD 4.2 million, a turnaround from break-even operating cash flow of AUD 5.8 million in FY2025, while cash on hand rose to AUD 21.4 million at year-end. The company highlighted regulatory and market expansion milestones, including U.K. approval for pediatric use of Penthrox for patients aged six and older, and the extension of Australia’s PBS eligibility to include nurse practitioners.
The Victorian government’s decision to make Penthrox free for IUD procedures in its women’s health hubs further bolstered demand. Management noted that the AUD 1.1 million partner stocking benefit would not recur in FY2027, and projected amortization expenses of about AUD 1 million related to capitalized registration costs for the pediatric indication.
Shares of Medical Developments International fell 1.94% to AUD 0.505 on Aug. 19, trimming gains from a 52-week range of AUD 0.365 to AUD 0.765. Analyst price targets for the stock range from AUD 0.71 to AUD 2.55, with a financial health score of 3.19 out of 5.
